Neurochemical studies suggest that
baclofen, an agonist at
GABA(B) receptors, may be useful for treatment of
nicotine dependence. However, its ability to selectively reduce
nicotine's abuse-related behavioral effects remains in question. We assessed effects of
baclofen doses ranging from 0.1 to 3mg/kg on
nicotine-induced conditioned place preferences (CPPs),
nicotine discrimination, locomotor activity and food-reinforced behavior in male Sprague-Dawley rats. The high dose of
baclofen (3mg/kg) totally eliminated food-reinforced responding and significantly decreased locomotor activity. Lower doses of
baclofen did not have
nicotine-like discriminative effects in rats trained to discriminate 0.4mg/kg
nicotine from saline under a fixed-ratio 10 schedule of food delivery. Lower doses of
baclofen also did not reduce discriminative stimulus effects of the training dose of
nicotine and did not significantly shift the dose-response curve for
nicotine discrimination. Rats treated with the high 3mg/kg dose of
baclofen did not express
nicotine-induced
CPP. These experiments, along with previous reports that
baclofen can reduce intravenous
nicotine self-administration behavior, confirm the potential utility of
baclofen as a tool for smoking cessation.